| Literature DB >> 28524372 |
Xiujie Liu1, Jing Su1, Yu Shi2, Ying Guo1, Imran Suheryani1, Shicong Zhao1, Yulin Deng1, Weiwei Meng3, Yan Chen3, Lili Sun3, Rongji Dai1.
Abstract
Preclinical Research Baogan Yihao (BGYH) is a traditional Chinese herbal medicine for the treatment of chronic liver diseases. In this study, the effects of BGYH on dimethylnitrosamine (DMN)-induced liver fibrosis were investigated using a rat model. BGYH alleviate liver damage, as indicated by decreased levels of AST, ALT, γ-GT, and AKP. BGYH also prevented collagen deposition and reduced pathological tissue injury in liver tissue. In fibrosis, high levels of α-SMA and TGF-β in liver tissue were markedly attenuated by BGYH. The inhibitory effect of BGYH on HSC-T6 proliferation demonstrated that BGYH exhibited significant hepatoprotective and antifibrogenic effects on DMN-induced liver injury. These findings suggest that BGYH may have therapeutic potential in the prevention and therapy of liver fibrosis. Drug Dev Res 78 : 155-163, 2017.Entities:
Keywords: Baogan Yihao; hepatoprotective; liver injury
Mesh:
Substances:
Year: 2017 PMID: 28524372 DOI: 10.1002/ddr.21388
Source DB: PubMed Journal: Drug Dev Res ISSN: 0272-4391 Impact factor: 4.360